OIG: CMS could lower Medicare payment for 15 Part B drugs
In a report this week, the Department of Health and Human Services’ Office of Inspector General identified 15 drug codes that in third-quarter 2022 met the Centers for Medicare & Medicaid Services’ criteria for substituting a lower Medicare price for certain Part B drugs. This means CMS may substitute either the widely available market price or 103% of the Average Manufacturers Price, whichever is less, when pricing these drugs, rather than using Average Sales Price plus 6%. The report does not identify the 15 drug codes.
Related News Articles
Blog
The editorial board of The Washington Post has published an opinion piece calling for payment cuts to hospitals and health systems as part of efforts to…
Blog
Earlier this month the Medicare Payment Advisory Commission (MedPAC) released its annual March report on the commission’s recommendations for Fiscal Year 2024…
Headline
The Centers for Medicare & Medicaid Services plans to extend the Medicare Advantage Value-Based Insurance Design Model for an additional five years,…
Headline
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere…
Headline
In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Services’ initial guidance implementing inflation rebates for…
Headline
Reps. Adrian Smith, R-Neb., and Terri Sewell, D-Ala., today introduced legislation that would repeal a Medicare rule that requires physicians at a Critical…